Abstract | BACKGROUND: OBJECTIVE:
Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allows a fixed dose regimen. With this characteristic apixaban overcomes many limitations and simplifies treatment of VTE eliminating the need for initial parenteral anticoagulant therapy and laboratory monitoring. RESULTS: Fixed-dose regimen of oral apixaban alone is as effective as conventional treatment regimen and is associated with a clinically relevant reduction of major bleeding. Extended anticoagulation with apixaban with either a treatment dose (5 mg twice daily) or thromboprophylactic dose (2.5 mg twice daily) reduces the risk of recurrent venous thromboembolism without increase in the rate of major bleeding. CONCLUSION: Therefore, apixaban provides a simple, effective and safe alternative to conventional acute or long-term treatment of VTE.
|
Authors | Pavel Poredos, Mateja Kaja Jezovnik |
Journal | Current drug targets
(Curr Drug Targets)
Vol. 19
Issue 6
Pg. 577-580
( 2018)
ISSN: 1873-5592 [Electronic] United Arab Emirates |
PMID | 25981607
(Publication Type: Comparative Study, Journal Article, Review)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Pyrazoles
- Pyridones
- apixaban
- Warfarin
- Heparin
|
Topics |
- Administration, Oral
- Anticoagulants
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Factor Xa Inhibitors
(administration & dosage, adverse effects, pharmacology)
- Hemorrhage
(chemically induced)
- Heparin
(administration & dosage, adverse effects)
- Humans
- Pulmonary Embolism
(drug therapy)
- Pyrazoles
(administration & dosage, adverse effects, pharmacology)
- Pyridones
(administration & dosage, adverse effects, pharmacology)
- Venous Thromboembolism
(drug therapy)
- Venous Thrombosis
(drug therapy)
- Warfarin
(administration & dosage, adverse effects)
|